A detailed history of Marshall Wace, LLP transactions in Alector, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 54,000 shares of ALEC stock, worth $103,680. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,000
Previous 52,609 2.64%
Holding current value
$103,680
Previous $238,000 5.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.34 - $6.58 $6,036 - $9,152
1,391 Added 2.64%
54,000 $252,000
Q2 2024

Aug 14, 2024

SELL
$4.19 - $6.23 $522,363 - $776,687
-124,669 Reduced 70.32%
52,609 $238,000
Q1 2024

May 15, 2024

BUY
$5.69 - $8.08 $1.01 Million - $1.43 Million
177,278 New
177,278 $1.07 Million
Q2 2022

Aug 15, 2022

BUY
$7.65 - $14.24 $908,146 - $1.69 Million
118,712 Added 23.22%
629,852 $6.4 Million
Q1 2022

May 16, 2022

SELL
$13.02 - $20.78 $7.42 Million - $11.8 Million
-569,714 Reduced 52.71%
511,140 $7.28 Million
Q4 2021

Feb 14, 2022

BUY
$19.35 - $25.54 $14.9 Million - $19.6 Million
768,293 Added 245.81%
1,080,854 $22.3 Million
Q3 2021

Nov 15, 2021

BUY
$21.65 - $39.49 $6.77 Million - $12.3 Million
312,561 New
312,561 $7.13 Million
Q1 2021

May 17, 2021

SELL
$14.84 - $22.23 $1.19 Million - $1.79 Million
-80,371 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$9.4 - $16.7 $479,841 - $852,484
-51,047 Reduced 38.84%
80,371 $1.22 Million
Q3 2020

Nov 16, 2020

BUY
$10.54 - $24.96 $402,427 - $952,997
38,181 Added 40.95%
131,418 $1.39 Million
Q2 2020

Aug 13, 2020

BUY
$21.87 - $33.11 $2.04 Million - $3.09 Million
93,237 New
93,237 $2.28 Million
Q1 2020

May 15, 2020

SELL
$16.25 - $35.28 $259,480 - $563,351
-15,968 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$14.17 - $20.3 $226,266 - $324,150
15,968 New
15,968 $275,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $159M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.